Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics

Bhatia, Sonam; Perou, Charles M.; Preall, Jonathan; Ha, Taehoon; Plenker, Dennis; Tuveson, David A.; Wilkinson, John E.; Spector, David L.

doi:10.1158/0008-5472.can-21-2807

Cited by 41 publications

(33 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kim et al 109 explored the pathway activity, microenvironment and clinical relevance of TNBC in their own biobank, and systematically proposed a predictive model and prognostic markers. Another tumor organoid biobank of TNBC provided comprehensive genome, transcriptome, and cellular characterization 110 . TNBC organoids lost the characteristics of normal breast PDO and were mostly rich in luminal progenitor cells.…”

Section: Overview Of Pdto Biobanksmentioning

confidence: 99%

Tumor organoid biobank-new platform for medical research

Song

2023

Sci Rep

View full text Add to dashboard Cite

Organoids are a new type of 3D model for tumor research, which makes up for the shortcomings of cell lines and xenograft models, and promotes the development of personalized precision medicine. Long-term culture, expansion and storage of organoids provide the necessary conditions for the establishment of biobanks. Biobanks standardize the collection and preservation of normal or pathological specimens, as well as related clinical information. The tumor organoid biobank has a good quality control system, which is conducive to the clinical transformation and large-scale application of tumor organoids, such as disease modeling, new drug development and high-throughput drug screening. This article summarized the common tumor types of patient-derived organoid (PDO) biobanks and the necessary information for biobank construction, such as the number of organoids, morphology, success rate of culture and resuscitation, pathological types. In our results, we found that patient-derived tumor organoid (PDTO) biobanks were being established more and more, with the Netherlands, the United States, and China establishing the most. Biobanks of colorectal, pancreas, breast, glioma, and bladder cancers were established more, which reflected the relative maturity of culture techniques for these tumors. In addition, we provided insights on the precautions and future development direction of PDTO biobank building.

show abstract

Section: Overview Of Pdto Biobanksmentioning

confidence: 99%

Tumor organoid biobank-new platform for medical research

Song

2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…After organoid coculture with pre-activated autologous CD8+ T cells, MAL2 depletion was found to enhance CD8+ T cell cytotoxicity [ 26 ]. Furthermore, Bhatia et al, developed long-term TNBC patient-derived organoids that imitated the extensively studied and evidently proven features of this aggressive MYC-driven, basal-like breast cancer and were largely comprised of luminal progenitor-like cells exhibiting hyperactivation of NOTCH and MYC signaling [ 27 ], while Chew et al, described low or undetectable Fibroblast Growth Factor Receptor 4 (FGFR4) immunohistochemical staining in TNBC patient-derived organoids [ 28 ]. Altogether, the study of TNBC patient-derived organoids may pave the way for novel and reliable discoveries in the field of TNBC pathogenesis that other in vitro or even in vivo culture models do not allow.…”

Section: The Role Of Patient-derived Organoids In the Understanding O...mentioning

confidence: 99%

The Role of Patient-Derived Organoids in Triple-Negative Breast Cancer Drug Screening

et al. 2023

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is one of the most aggressive breast cancer subtypes, with a grave prognosis and few effective treatment options. Organoids represent revolutionary three-dimensional cell culture models, derived from stem or differentiated cells and preserving the capacity to differentiate into the cell types of their tissue of origin. The current review aims at studying the potential of patient-derived TNBC organoids for drug sensitivity testing as well as highlighting the advantages of the organoid technology in terms of drug screening. In order to identify relevant studies, a literature review was conducted using the MEDLINE and LIVIVO databases. The search terms “organoid” and “triple-negative breast cancer” were employed, and we were able to identify 25 studies published between 2018 and 2022. The current manuscript represents the first comprehensive review of the literature focusing on the use of patient-derived organoids for drug sensitivity testing in TNBC. Patient-derived organoids are excellent in vitro study models capable of promoting personalized TNBC therapy by reflecting the treatment responses of the corresponding patients and exhibiting high predictive value in the context of patient survival evaluation.

show abstract

“…Furthermore, approximately 5–10% of the most aggressive form of breast cancer, triple negative breast cancer (TNBC), is associated with NRR or PEST domain mutations in NOTCH1 and NOTCH2 [ 37 , 38 ], but TNBC is also associated with elevated expression of JAGGED1, NOTCH1, NOTCH3 or NOTCH4, which in turn is associated with poor clinical prognosis [ 39 , 40 , 41 , 42 ]; for review see [ 43 ]. TNBC patient-derived organoids show hyperactivated Notch signaling in comparison to control organoids [ 44 ]. In other forms of breast cancer, such as estrogen receptor (ER)- or HER2-positive breast cancer, Notch signaling may initially be lower, but increases in response to endocrine therapies aiming at reducing ER activity or to therapy using HER2-blocking antibodies (trastuzumab) [ 45 , 46 , 47 , 48 , 49 , 50 ]; for review see [ 51 ].…”

Section: Dysregulated Notch Signaling In Cancermentioning

confidence: 99%

Roles of Notch Signaling in the Tumor Microenvironment

D’Assoro

Leon‐Ferre

Braune

et al. 2022

IJMS

View full text Add to dashboard Cite

The Notch signaling pathway is an architecturally simple signaling mechanism, well known for its role in cell fate regulation during organ development and in tissue homeostasis. In keeping with its importance for normal development, dysregulation of Notch signaling is increasingly associated with different types of tumors, and proteins in the Notch signaling pathway can act as oncogenes or tumor suppressors, depending on the cellular context and tumor type. In addition to a role as a driver of tumor initiation and progression in the tumor cells carrying oncogenic mutations, it is an emerging realization that Notch signaling also plays a role in non-mutated cells in the tumor microenvironment. In this review, we discuss how aberrant Notch signaling can affect three types of cells in the tumor stroma—cancer-associated fibroblasts, immune cells and vascular cells—and how this influences their interactions with the tumor cells. Insights into the roles of Notch in cells of the tumor environment and the impact on tumor-stroma interactions will lead to a deeper understanding of Notch signaling in cancer and inspire new strategies for Notch-based tumor therapy.

show abstract

Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics

Cited by 41 publications

References 87 publications

Tumor organoid biobank-new platform for medical research

Tumor organoid biobank-new platform for medical research

The Role of Patient-Derived Organoids in Triple-Negative Breast Cancer Drug Screening

Roles of Notch Signaling in the Tumor Microenvironment

Contact Info

Product

Resources

About